Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Echinococcus granulosus | peptidase Clp S14 family | 0.0035 | 0.0059 | 0.0059 |
Onchocerca volvulus | 0.0569 | 1 | 1 | |
Mycobacterium ulcerans | ATP-dependent Clp protease proteolytic subunit | 0.0054 | 0.0406 | 0.5 |
Loa Loa (eye worm) | hypothetical protein | 0.0181 | 0.2768 | 0.2462 |
Mycobacterium leprae | PROBABLE ATP-DEPENDENT CLP PROTEASE PROTEOLYTIC SUBUNIT 2 CLPP2 (ENDOPEPTIDASE CLP 2) | 0.0054 | 0.0406 | 1 |
Loa Loa (eye worm) | hexokinase | 0.0569 | 1 | 1 |
Echinococcus granulosus | hexokinase | 0.0569 | 1 | 1 |
Trypanosoma brucei | hexokinase | 0.0569 | 1 | 0.5 |
Echinococcus multilocularis | hexokinase type 2 | 0.0569 | 1 | 1 |
Echinococcus multilocularis | hexokinase | 0.0569 | 1 | 1 |
Plasmodium falciparum | hexokinase | 0.0569 | 1 | 1 |
Brugia malayi | Hexokinase family protein | 0.0357 | 0.6049 | 0.5882 |
Onchocerca volvulus | 0.0569 | 1 | 1 | |
Echinococcus granulosus | hexokinase | 0.0569 | 1 | 1 |
Chlamydia trachomatis | ATP-dependent Clp protease proteolytic subunit | 0.0054 | 0.0406 | 0.5 |
Treponema pallidum | hexokinase (hxk) | 0.0569 | 1 | 1 |
Echinococcus multilocularis | ATP dependent Clp protease proteolytic subunit | 0.0054 | 0.0406 | 0.0406 |
Entamoeba histolytica | hexokinase 1 | 0.0569 | 1 | 0.5 |
Loa Loa (eye worm) | hexokinase | 0.0569 | 1 | 1 |
Trypanosoma brucei | hexokinase, putative | 0.0569 | 1 | 0.5 |
Loa Loa (eye worm) | hexokinase type II | 0.0569 | 1 | 1 |
Brugia malayi | Hexokinase family protein | 0.0176 | 0.2678 | 0.2368 |
Trypanosoma cruzi | hexokinase, putative | 0.0569 | 1 | 0.5 |
Schistosoma mansoni | peptidase Clp (S14 family) | 0.0054 | 0.0406 | 0.0406 |
Entamoeba histolytica | hexokinase 2 | 0.0569 | 1 | 0.5 |
Leishmania major | hexokinase, putative | 0.0569 | 1 | 0.5 |
Mycobacterium tuberculosis | Probable ATP-dependent CLP protease proteolytic subunit 2 ClpP2 (endopeptidase CLP 2) | 0.0035 | 0.0059 | 0.5 |
Loa Loa (eye worm) | hexokinase | 0.0357 | 0.6049 | 0.5882 |
Loa Loa (eye worm) | hypothetical protein | 0.0388 | 0.6629 | 0.6486 |
Brugia malayi | hexokinase type II | 0.0181 | 0.2768 | 0.2462 |
Trypanosoma brucei | hexokinase | 0.0569 | 1 | 0.5 |
Echinococcus multilocularis | hexokinase | 0.0569 | 1 | 1 |
Echinococcus granulosus | ATP dependent Clp protease proteolytic subunit | 0.0054 | 0.0406 | 0.0406 |
Echinococcus multilocularis | peptidase Clp (S14 family) | 0.0035 | 0.0059 | 0.0059 |
Mycobacterium ulcerans | ATP-dependent Clp protease proteolytic subunit | 0.0054 | 0.0406 | 0.5 |
Chlamydia trachomatis | ATP-dependent Clp protease proteolytic subunit | 0.0054 | 0.0406 | 0.5 |
Brugia malayi | Hexokinase family protein | 0.0569 | 1 | 1 |
Trypanosoma cruzi | hexokinase, putative | 0.0569 | 1 | 0.5 |
Loa Loa (eye worm) | hexokinase | 0.0176 | 0.2678 | 0.2368 |
Wolbachia endosymbiont of Brugia malayi | ATP-dependent Clp protease proteolytic subunit | 0.0054 | 0.0406 | 0.5 |
Echinococcus multilocularis | hexokinase | 0.0569 | 1 | 1 |
Onchocerca volvulus | 0.0569 | 1 | 1 | |
Mycobacterium tuberculosis | Probable ATP-dependent CLP protease proteolytic subunit 1 ClpP1 (endopeptidase CLP) | 0.0035 | 0.0059 | 0.5 |
Echinococcus granulosus | hexokinase type 2 | 0.0569 | 1 | 1 |
Toxoplasma gondii | hexokinase | 0.0569 | 1 | 1 |
Plasmodium vivax | hexokinase, putative | 0.0569 | 1 | 1 |
Schistosoma mansoni | hexokinase | 0.0569 | 1 | 1 |
Leishmania major | hexokinase, putative | 0.0569 | 1 | 0.5 |
Loa Loa (eye worm) | hypothetical protein | 0.0181 | 0.2768 | 0.2462 |
Echinococcus granulosus | hexokinase | 0.0569 | 1 | 1 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
GI50 (functional) | = 43 nmol/L | Antiproliferative activity against human MOLM13 cells after 72 hrs by WST-1 assay | ChEMBL. | 18835166 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.